Global Blood Glucose Monitoring Systems Market 2018-2024

  • Product Code:
    RP-ID-10078118
  • Published Date:
    Mar 2019
  • Region:
    Global
  • Pages:
    100
  • Category:
    Healthcare & Pharmaceuticals
  • Publisher:
    Infoholic Research
Global Blood Glucose Monitoring Systems Market – Drivers, Restraints, Opportunities, Trends, and Forecast: 2018–2024
Overview: Blood glucose monitoring is an integral part of the standard diabetes care, and it is very helpful in controlling the glucose levels in individuals with diabetes and impaired glucose tolerance. The incidence of diabetes is increasing globally, and around 90% of the patients have type 2 diabetes mellitus with approximately one-fifth of the people undergoing insulin treatment. Self-monitoring blood glucose (SMBG) systems and continuous glucose monitoring (CGM) systems are two major types of blood glucose monitoring systems.
The market for blood glucose monitoring systems is driven by increasing incidence of diabetes across various geographies, huge surge in the aging population, and increasing product launch and approvals. Increasing collaboration and funding to develop innovative devices and raising awareness among the patients are providing an opportunity for the market growth. Product recalls and inadequate reimbursements are few of the factors that may hamper the market growth to an extent.
Market Analysis: The “Global Blood Glucose Monitoring Systems” market is estimated to witness a CAGR of 6.7% during the forecast period 2018–2024. The global market is analyzed based on four segments – products, applications, end-users, and regions.
Regional Analysis: The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (RoW). North America is the major shareholder in the global blood glucose monitoring systems market, followed by Europe. The Asia Pacific region is expected to grow at a high CAGR during the forecast period due to an upsurge in access to health care services, increasing patient pool, raising awareness among patients, and growing healthcare expenditure. According to the Asian Diabetes Prevention Initiative, nearly 60% of the total diabetic population resides in Asia. It also estimates that 65.1 million adults in India and 113.9 million adults in China have diabetes.
Product Analysis: The blood glucose monitoring systems market, by product, is segmented into self-monitoring blood glucose (SMBG) systems and continuous glucose monitoring (CGM) systems. SMBG systems occupied a significant market share in 2017, and CGM systems are expected to grow at a high CAGR during the forecast period. Increasing adoption of minimally invasive procedures makes it the fastest growing segment during the forecast period.
Application Analysis: The market, by applications, is segmented into type 1 diabetes, type 2 diabetes, and gestational diabetes. Type 2 diabetes occupied a significant market share in 2017 and is expected to remain the same for the next 5 years. This is due to growing patient base for type 2 diabetes and increasing launch of the advanced product in this segment.
End-users Analysis: The market, by end-users, is segmented into hospitals, homecare, private clinics, and others. Among various end-users, homecare occupied a significant market share and is expected to remain the same during the forecast period.
Key Players: Medtronic plc, Johnson and Johnson, Abbott Laboratories, F. Hoffmann-La Roche Ltd., PHC Holdings Corporation, Ypsomed Holding, Dexcom, Acon Laboratories, Trividia Health Inc., Arkray Inc., Sanofi S.A., Terumo Medical Corporation, Prodigy Diabetes Care LLC, and niche players.
Competitive Analysis: The market has a large number of medium and small players that offer innovative products and has immense growth opportunity, especially in the emerging countries. The key market players are taking advantage of product approvals and new product launches, making their strategies to increase the market share. For instance, in September 2017, the US FDA approved FreeStyle Libre Flash Glucose Monitoring System, the first continuous glucose monitoring system that can be used by adult patients to make diabetes treatment decisions without calibration using a blood sample from the fingertip. In February 2018, Roche Diabetes Care India announced the launch of its new glucometer Accu-Chek Instant S, which marks the entry of the organization into the mass market segment in diabetes self-monitoring.
Benefits: The report provides complete details about the usage and adoption rate of blood glucose monitoring systems in various therapeutic verticals and regions. With that, key stakeholders can know about the major trends, drivers, investments, and vertical player’s initiatives. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.
Key Stakeholders:

Table of Contents
1 Industry Outlook 8
1.1 Market Overview 8
1.2 Total addressable market 10
2 Report Outline 12
2.1 Report Scope 12
2.2 Report Summary 12
2.3 Research Methodology 13
2.4 Report Assumptions 13
3 Market Snapshot 15
3.1 Market Definition – Infoholic Research 15
3.2 Advantages of blood glucose monitoring systems 15
3.3 Segmented Addressable Market (SAM) 15
3.4 Trends of the blood glucose monitoring systems market 15
3.5 Related Markets 17
3.5.1 Insulin pump 17
3.5.2 Smart insulin pen 17
3.5.3 Insulin Syringes 17
4 Market Outlook 18
4.1 Evolution of Blood Glucose Monitoring 18
4.2 Market segmentation 18
4.3 PEST Analysis 18
4.4 Porter 5(Five) Forces 19
5 Market Characteristics 21
5.1 DRO – Global Blood Glucose Monitoring Systems Market Dynamics 21
5.1.1 Drivers 21
5.1.1.1 Increasing incidence of diabetes across various geographies 21
5.1.1.2 Increasing number of product launch and approvals 22
5.1.1.3 Huge surge in the aging population 22
5.1.2 Opportunities 23
5.1.2.1 New collaboration and funding to develop new devices 23
5.1.2.2 Growing patient awareness 23
5.1.3 Restraints 24
5.1.3.1 High cost and inadequate reimbursement 24
5.1.3.2 Product recalls 24
5.2 DRO – Impact Analysis 24
5.3 Key Stakeholders 25
6 Products: Market Size & Analysis 27
6.1 Overview 27
6.2 Self-monitoring Blood Glucose Systems 28
6.3 Continuous Glucose Monitoring Systems 29
7 Application: Market Size & Analysis 31
7.1 Overview 31
7.2 Type 1 Diabetes 32
7.3 Type 2 Diabetes 32
7.4 Gestational Diabetes 33
8 End-User: Market Size & Analysis 34
8.1 Overview 34
8.2 Hospitals 35
8.3 Homecare 35
8.4 Private clinics 35
8.5 Others 36
9 Regions: Market Size and Analysis 37
9.1 Overview 37
9.2 North America 38
9.3 Europe 40
9.4 Asia Pacific 41
9.5 Rest of the World 43
10 Competitive Landscape 45
10.1 Overview 45
11 Vendor Profiles 48
11.1 Medtronic plc 48
11.1.1 Overview 48
11.1.2 Medtronic plc: Recent Developments 49
11.1.3 Business Units 56
11.1.4 Geographic Revenue 57
11.1.5 Business Focus 58
11.1.6 SWOT Analysis 58
11.1.7 Business Strategies 59
11.2 Abbott Laboratories 60
11.2.1 Overview 60
11.2.2 Abbott Laboratories: Recent Developments 61
11.2.3 Business Units 63
11.2.4 Geographic Presence 65
11.2.5 Business Focus 65
11.2.6 SWOT Analysis 66
11.2.7 Business Strategies 66
11.3 Johnson and Johnson 67
11.3.1 Overview 67
11.3.2 Business Units 71
11.3.3 Geographic Revenue 72
11.3.4 Business Focus 73
11.3.5 SWOT Analysis 74
11.3.6 Business Strategies 74
11.4 F.Hoffmann-La Roche Ltd. 75
11.4.1 Overview 75
11.4.2 Business Unit 78
11.4.3 Geographic Presence 78
11.4.4 Business Focus 79
11.4.5 SWOT Analysis 79
11.4.6 Business Strategy 80
12 Companies to Watch for 81
12.1 Dexcom 81
12.1.1 Overview 81
12.2 PHC Holdings Corporation 82
12.2.1 Overview 82
12.3 Ypsomed Holding 85
12.3.1 Overview 85
12.4 B. Braun Melsungen AG 86
12.4.1 Overview 86
12.5 Trividia Health, Inc. 88
12.5.1 Overview 88
12.6 Acon Laboratories 89
12.6.1 Overview 89
12.7 Sanofi S.A. 90
12.7.1 Overview 90
12.8 Arkray, Inc. 93
12.8.1 Overview 93
12.9 Nova Biomedical Corporation 94
12.9.1 Overview 94
12.10 Prodigy Diabetes Care, LLC 95
12.10.1 Overview 95
12.11 Terumo Medical Corporation 96
12.11.1 Overview 96
Annexure 99
 Acronyms 99

Please enter your personal details below
*
I want to buy this report
I am willing to know the scope of research
I have customized query over this report
Medtronic plc, Johnson and Johnson, Abbott Laboratories, F. Hoffmann-La Roche Ltd., PHC Holdings Corporation, Ypsomed Holding, Dexcom, Acon Laboratories, Trividia Health Inc., Arkray Inc., Sanofi S.A., Terumo Medical Corporation, Prodigy Diabetes Care LLC, and niche players
Please enter your personal details below
*
I want to buy this report
I am willing to know the scope of research
I have customized query over this report

Related Reports